Elliot M. Stieglitz

Hematology | Oncology

1825 4th St
San Francisco, CA 94143

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 82 publications

Ribonucleotide Reductase Inhibition Overcomes FLT3 Inhibitor Resistance in Acute Myeloid Leukemia.

Ribonucleotide Reductase Inhibition Overcomes FLT3 Inhibitor Resistance in Acute Myeloid Leukemia.

Journal: bioRxiv : the preprint server for biology

Published: August 01, 2026

HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL.

HLH-like syndromes associate with increased risk of death and CD19-negative relapse post-CAR T in pediatric B-ALL.

Journal: Blood advances

Published: March 24, 2026

Trametinib Therapy for Hypertrophic Cardiomyopathy and Pulmonary Hypertension in a Child With RAF1-Related Noonan Syndrome (p.Ser257Leu): A Case Report.

Trametinib Therapy for Hypertrophic Cardiomyopathy and Pulmonary Hypertension in a Child With RAF1-Related Noonan Syndrome (p.Ser257Leu): A Case Report.

Journal: Clinical case reports

Published: February 06, 2026

Therapy by omission: observation as a strategy in JMML.

Therapy by omission: observation as a strategy in JMML.

Journal: Blood

Published: January 22, 2026

Therapeutic Targeting of IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation in Juvenile Myelomonocytic Leukemia.

Therapeutic Targeting of IL-17A-Driven PTGS2/NLRP3 Inflammasome Activation in Juvenile Myelomonocytic Leukemia.

Journal: Blood

Published: November 25, 2025

Daple-FLT3 (CCDC88C-FLT3) gene fusion requires the coiled-coil domain for maximal activation and pericentrosomal localization.

Daple-FLT3 (CCDC88C-FLT3) gene fusion requires the coiled-coil domain for maximal activation and pericentrosomal localization.

Journal: bioRxiv : the preprint server for biology

Published: November 19, 2025

Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

Dynamic genetic and nongenetic RAS pathway activation drives resistance to FLT3 and BCL2 inhibitor therapy.

Journal: Blood

Published: November 17, 2025

Concurrent Juvenile Myelomonocytic Leukemia and Gliomas in Patients With Neurofibromatosis Type 1.

Concurrent Juvenile Myelomonocytic Leukemia and Gliomas in Patients With Neurofibromatosis Type 1.

Journal: Pediatric blood & cancer

Published: August 19, 2025

Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia.

Multi-selective RAS(ON) Inhibition Targets Oncogenic RAS Mutations and Overcomes RAS/MAPK-Mediated Resistance to FLT3 and BCL2 Inhibitors in Acute Myeloid Leukemia.

Journal: bioRxiv : the preprint server for biology

Published: July 15, 2025

Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.

Multiselective RAS(ON) inhibition targets oncogenic RAS and overcomes RAS-mediated resistance to FLT3i and BCL2i in AML.

Journal: Blood

Published: July 07, 2025

Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia.

Molecular Plasticity Results in Oncofetal Reprogramming and Therapeutic Vulnerabilities in Juvenile Myelomonocytic Leukemia.

Journal: Blood cancer discovery

Published: July 02, 2025

Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.

Clinical and molecular characterization of patients with juvenile myelomonocytic leukaemia.

Journal: British journal of haematology

Published: May 19, 2025

Showing 1-12 of 82

Last Updated: 09/26/2026